MediPharm Labs Corp.

LABS

CA58504D1006

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 03:12:14 2024-05-15 pm EDT			5-day change	1st Jan Change
0.08 ^CAD	-5.88%		-5.88%	+23.08%

01:50pm	MediPharm Labs Q1 Gross Profit, Rise	MT
12:36pm	MediPharm Labs Corp. Brief: Anticipates further improvement on profitability in 2024 with plans being implemented to improve Adjusted EBITDA by a further $1-$2 Million	MT

MediPharm Labs Corp. Reports Earnings Results for the Full Year Ended December 31, 2023

March 27, 2024 at 07:32 am EDT

MediPharm Labs Corp. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CAD 36.82 million compared to CAD 24.98 million a year ago.

Revenue was CAD 33.06 million compared to CAD 22.12 million a year ago. Net loss was CAD 13.08 million compared to CAD 29.98 million a year ago. Basic loss per share from continuing operations was CAD 0.04 compared to CAD 0.11 a year ago.

Latest news about MediPharm Labs Corp.

MediPharm Labs Q1 Gross Profit, Rise	07:50am	MT
MediPharm Labs Corp. Brief: Anticipates further improvement on profitability in 2024 with plans being implemented to improve Adjusted EBITDA by a further $1-$2 Million	06:36am	MT
MediPharm Labs Corp. Brief: Revenue increased 67% to $9.8 Million during the three months ended March 31, 2024, versus revenue for the same quarter in 2023 of $5.8 Million	06:32am	MT
MediPharm Labs Narrows Q4 Loss, Revenue Grows; Up 10.5%	Mar. 27	MT
MediPharm Labs Narrows Q4 Loss, Revenue Grows	Mar. 27	MT
Transcript : MediPharm Labs Corp., Q4 2023 Earnings Call, Mar 27, 2024	Mar. 27
MediPharm Labs Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
MediPharm Labs Corp. Brief: Q4 Revenue $9.131 Million; Says Annual Revenue and Adjusted EBITDA Improve by 50%	Mar. 27	MT
MediPharm Labs Offers Update on German Cannabis Legalization; Up Nearly 6%	Mar. 25	MT
IM Cannabis Corp. Brief: Notes This Provides IMC Germany with a "Unique Opportunity" to further accelerate growth in 2024 after delivering 180% growth in 2023	Mar. 25	MT
IM Cannabis Corp. Brief: Adds By rescheduling medical cannabis, from a narcotic to a regular prescription, the German medical cannabis market is Expected to deliver "Strong" growth	Mar. 25	MT
IM Cannabis Corp. Brief: Says Expects "Accelerated Growth" in Germany from that Country's "Groundbreaking" Cannabis Legalization	Mar. 25	MT
MediPharm Labs Offers Update on German Cannabis Legalization	Mar. 25	MT
MediPharm Labs Corp. Brief: Says "Historic change is a significant positive step in removing the stigma related to medical cannabis"	Mar. 25	MT
MediPharm Labs Corp. Brief: Providing Update on German Cannabis Legalization	Mar. 25	MT
MediPharm Labs Provides Update on German Cannabis Legalization	Mar. 25	CI
MediPharm Labs Corp. Says Achieved Pharmaceutical GMP Certification with Brazilian Health Authority	Feb. 07	MT
MediPharm Labs Corp. Brief: Says Achieved Pharmaceutical GMP Certification with Brazilian Health Authority	Feb. 07	MT
Transcript : MediPharm Labs Corp., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
MediPharm Labs Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
MediPharm Labs Corp. Updated On $9 Million Settlement Agreement; All Tilray Shares Sold and Converted to Cash	23-10-25	MT
MediPharm Labs Corp. Brief: Updating on $9 Million Settlement Agreement; All Tilray Shares Sold and Converted to Cash	23-10-25	MT
Tilray Brands, Inc. acquired 1000652011 Ontario Inc. from MediPharm Labs Corp. for CAD 8.5 million.	23-10-03	CI
MediPharm Labs Corp. Says Settled an Outstanding Claim for $9 Million	23-10-02	MT
MediPharm Labs Corp. Brief: Says Settled an Outstanding Claim for $9 Million	23-10-02	MT

Chart MediPharm Labs Corp.

Duration

Period

More charts

Company Profile

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. The Company's subsidiary, Harvest Medicine provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for MediPharm Labs Corp.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.085 CAD

Average target price

0.1 CAD

Spread / Average Target

+17.65%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
MEDIPHARM LABS CORP.	+23.08%	25.17M
DONG-E-E-JIAO CO.,LTD.	+45.15%	6.34B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-14.00%	4.61B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+9.54%	3.39B
TASLY PHARMACEUTICAL GROUP CO., LTD	-8.99%	3.29B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+50.03%	2.02B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-6.97%	1.73B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-0.31%	1.67B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+50.00%	1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-10.61%	1.59B

Alternative Medicine